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Erectile dysfunction (ED) is a common complaint in hypertensive men and can represent a systemic vascular disease, an adverse
eﬀect of antihypertensive medication or a frequent concern that may impair drug compliance. ED has been considered an early
marker of cardiovascular disease. The connection between both conditions seems to be located in the endothelium, which may
become unable to generate the necessary dilatation in penile vascular bed in response to sexual excitement, producing persistent
impairmentinerection.Ontheotherhand,therealinﬂuenceofantihypertensivedrugsinerectilefunctionstilldeservesdiscussion.
Therefore, regardless of ED mechanism in hypertension, early diagnosis and correct approach of sexual life represent an important
step of cardiovascular evaluation which certainly contributes for a better choice of hypertension treatment, preventing some
complications and restoring the quality of life.
1.Introduction
Erectile dysfunction (ED) has been deﬁned according to Na-
tionalInstituteofHealthfrom1993asthepersistentinability
to reach or maintain and penile rigidity enough for sexual
satisfaction [1]. ED has a high prevalence around the world
and a huge impact on quality of life of men and their part-
ners [2]. With the increment of life expectation and aging
of population, ED burden is supposed to increase in the
upcoming years [3].
Common risk factor categories associated with sexual
dysfunction exist for men and women including individual
general health status, diabetes mellitus, cardiovascular dis-
ease, other genitourinary disease, psychiatric/psychological
disorders, other chronic disease, and sociodemographic con-
ditions. Actually, vasculogenic ED is considered part of a
systemic vasculopathy and has a known relation with cardi-
ovascular risk factors such as hypertension, diabetes, dyslip-
idemia,andsmoking.EDhasbeenconsideredanearlymark-
er of cardiovascular risk that could precede traditional clini-
cal manifestations of atherosclerosis, indicating the presence
of vascular disease. In addition, ED could alert clinicians
to the presence of unknown risk factors and an increased
cardiovascular risk. Thus, ED could oﬀer the opportunity to
implementadequatetherapeuticeﬀortstominimize thebur-
den of major cardiovascular disease such as myocardium in-
farction and stroke [4].
As ED is highly prevalent and deeply impacts overall
health of sexually active men, sexual function should be part
of anamneses in all hypertensive subjects, especially those
over 50 years. Ideally, such investigation could be held before
starting therapeutic. To stimulate this attitude, the main
objectives of this paper are to review some aspects linking
ED and hypertension, including arterial hypertension as a
risk factor for ED, ED as a marker of cardiovascular risk, ED
and antihypertensive drugs, its possible negative impact in
therapeutic adhesion, and lastly, actual therapeutic approach
of hypertensive men with ED.
2. EDPrevalence andImpact aroundthe World
ED prevalence was surprisingly high at the end of the classic
Massachusetts Male Aging Study (MMAS) reaching almost2 International Journal of Hypertension
40% among men at theirs 6th decade of life. Those numbers
were similar in more recent publications over the world
[5] and also in developing countries [6], projecting the
assumption that over 30 million American citizens suﬀer
from some level of sexual dysfunction [5].
Prevalence’s numbers vary according to characteristics
of the population studied and the method used to access
erectile function. Some trials have used a single question
about sexual satisfaction while others have adopted validated
questionnaires like International Index of Erectile Function
(IIEF) that could check all ﬁve major domains of sexuality:
sexual desire, erectile function, orgasmic function, inter-
course satisfaction, and overall satisfaction with sexual life
[3].
Besides this high prevalence, before oral therapy with
phosphodiesterase-5 (PDE5) inhibitors, less than 1/4o fm e n
with ED search for medical help [7]. The most frequent
reasons for such passiveness were belief that lack of complete
erection was part of a normal aging, sexual inactivity caused
by widowhood, lack of perception of ED as a medical disor-
der, ashamed to talk with a doctor about sexuality, lack of an
eﬀective treatment for most cases. Probably the real impact
of ED was even greater with a strong relationship with aging
and some authors estimated that almost half of 70-year-old
m e nl i v ew i t hs o m ed e g r e eo fE D[ 5, 6].
After introduction of sildenaﬁl in therapeutic market in
1998 [8], a revolution shook this scenario and search for
oﬃces increased as well as medical knowledge about ED and
the way physicians treat their patients [9]. From the label
of having an psychological illness to an exhaustive, invasive
and mostly usefulness series of complementary exams, the
evaluation post-PDE5 inhibitors turned to a simple iden-
tiﬁcationofriskfactors[10],theircontrolwheneverpossible,
and improvement of sexual performance through PDE5 in-
hibitors prescriptions [11] that quickly became one sales
blockbuster.
As a consequence of PDE5 inhibitors basic develop-
ment studies, erectile process was better understood and
several papers from the last decade stressed the association
between ED and vascular disease identiﬁed by functional
and structural changes related to atherosclerosis process
[12]. These evidences, in addition to the mechanism of ac-
tion of such drugs—based on dilation of muscular layers
of arteries and cavernous spaces by the blockage of cyclic
GMP degradation—point out ED as part of a generalized
vasculopathy [13].
It seems important to remember the complexity of
erection physiopathology as well as of the hypothetical link
withcardiovasculardisease—endothelialdysfunction—since
multiple factors could cause ED and interfere in the delicate
balance of mediators released from endothelium [14]. But
psychological aspects of man sexuality interfere in all steps
of sexual disorders and could complicate diagnostic attempts
orharmtherapyeﬀorts.Itisreallyimportanttoindividualize
each complain in order to understand the situation and oﬀer
the best medical approach.
New therapeutic strategies and molecular targets will
help to improve quality of erections and sexual satisfaction.
In order to cure ED, if it is really possible, some recent
studies propose regular use of drugs with proved endothelial
action such as statins or PDE 5 inhibitors, taken daily instead
of on demand [15], in order to provide sensation of been
alwaysreadyforintercourse.Medicaladvancesapart,thebest
treatment for ED remain its prevention. In this sense, men
knowledge about cardiovascular health and the relationship
of ED with traditional risk factors should help physicians to
motivate therapeutic adhesion and adoption of a healthier
way of life [16].
3.EDandCardiovascularRisk
Several traditional risk factors were related to ED in medical
literature with some evidences coming from well designed
epidemiological trials. Age seems to be the clearest risk factor
with strong association with the presence and severity of
ED [5]. After adjusting for age, the correlation between ED
and modiﬁable risk factors—hypertension, diabetes, hyper-
lipidemia, obesity, sedentary, and smoking—remained sig-
niﬁcant [17]. The increase of ED’s prevalence with aging is
followedbyatheroscleroticlesionsinvasculartree[18].Most
men with hypothetic vasculogenic ED present at least one
traditional cardiovascular risk factor [19]. These evidences
allowed the consideration of ED as a clinical manifestation of
a functional (lack of vasodilation) or structural abnormality
in penile circulation as component of a systemic vasculopa-
thy [20].
Erection is a complex psiconeurovascular process and
involves several system interactions that converge to an
increase in hypogastrian-penian blood ﬂow and subsequent
activation of veno-occlusive mechanism of corpus caver-
nosum [21]. It is well known that the blood increment
towards cavernous tissues necessary for a rigid erection is
huge and even small hemodynamic disturbances could pro-
ducesexualdysfunction[22].So,traditionalriskfactorssuch
as hypertension, diabetes, and hyperlipidemia could con-
tribute for ED development or worsening even in situations
where psychological etiology seems more likely.
In addition, penile erectile tissue’s integrity depends on
oxygen tension ﬂuctuations that occur during physiologic
erections. As a consequence of regular erections, several cy-
tokines, vasoactive, and growth factors keep a suitable envi-
ronment for erectile tissue with a protective eﬀect over stro-
ma and muscular cells of this region [23]. In a pathological
condition causing the absence of stimulated or physiological
erections and abolishing such stimulus, there would be a
structuralchangeintissuecompositionwithdeleteriouscon-
sequences on erectile capacity [24].
Some trials have shown the presence of vascular disease
in men suﬀering from vasculogenic ED but without tradi-
tional risk factors, pointing out ED as a clinical early cardi-
ovascular risk marker [25]. Particularly among men less
than 60 years old, ED seems to act as a risk factor inde-
pendentoftraditionalmarkers[26]. More recently, laborato-
rial markers such as dimetilarginin asymmetric (ADMA)
[27] and C-reactive protein were reported higher in ED
men when compared with men without ED and similar risk
factors [28].International Journal of Hypertension 3
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Figure 1: Relationship between hypertension and erectile dysfunction. PDE5, phosphodiesterase 5.
On the other hand, as a consequence of its multifacto-
rial aspect, several conditions could promote ED without
systemic vascular involvement such as pelvic surgeries,
depression, Peyronie’s disease, and prostatism. Probably
this aspect is one among others to explain the lack of
additional contribution of ED over traditional risk factors
(Framingham score) during cardiovascular evaluation in
some reports [29]. Other possible explanations were the
characteristics of study population, method of assessing risk
factors and the diagnostic tool used for ED diagnostic.
Other risk factors have been related to ED. Sedentarism,
obesity, and smoking have been implicated in the etiology
of ED, and an approach of these risk factors has been able
to reverse ED and restore normal erectile function [30].
Metabolic syndrome and waist-to-rip ratio have been asso-
ciated to more severe ED among those over 50 years old [31].
SleepdisorderswerealsomoreprevalentamongEDmenand
their treatment could help in recovering sexual satisfaction
[32].
4.ErectileDysfunctionand
Systemic Hypertension
Hypertension is considered one of the most hazardous car-
diovascular risk factors and it is a frequent comorbidity of
men with ED [33]. One of the ﬁrst studies to ask about sex-
ual function among hypertensives was the classic TOMHS
(The Treatment of Mild Hypertension Study)[ 34] and its re-
sults contributed to the false belief that ED was rare in this
populationsincetheyfoundonly12.2%ofmenreferringany
degree of sexual dysfunction at inclusion. TOMHS excluded
subjects with comorbidities like diabetes or hyperlipidemia,
older and moderate or severe hypertension. At the end of
TOMHS, ED was more frequent among those with more
antihypertensive drugs or systolic pressure over 140mm Hg.
Other trials also refuse the high prevalence of ED among
hypertensives[35]probablyduetocharacteristicsofthesam-
ple and the method to diagnose ED.
On the other hand, Jensen et al. observed that the main
reason for ED among hypertensive individuals were penile
circulation disability (found in 89%), probably due to athe-
rosclerosis [36]. Burchardt and coworkers using IIEF-5 to
access erectile function among hypertensive men, aging from
34 to 75 years old, found 68.3% of ED prevalence [33].
Feldmanetal.stressedthesigniﬁcantassociationbetweenED
and traditional risk factors for coronary artery disease, like
hypertension, smoking, overweight and hyperlipidemia [5].
Giuliano et al. performed a survey of 7689 patients (mean
age 59 years) using the Sexual Health Inventory in Men
(SHIM)questionnaire.In3906menwithhypertensionalone
(no diabetes), ED was present in 67% (deﬁned as a SHIM
score of 21) [37]. Doumas et al. studied Greek hypertensive
patients and identiﬁed ED in 35.2%, which correlated with
age, duration of hypertension and use of antihypertensive
drugs [38]. Mittawae et al. evaluated the sexual function of
800 Egyptian hypertensive subjects and found ED in 43.2%
and duration of hypertension was the variable with stronger
correlation with ED severity [39]. Recently, Chang et al.
suggested that ED severity was associated with number of
risk factors, including criteria for metabolic syndrome [40].
A retrospective analysis of placebo group of Prostate Cancer
Prevention Trial estimated the 5-year risk of coronary events
among men with ED in 11% which, in terms of preventive
medicine, means that ED could be considered an equivalent
of coronary disease [41].
5.ErectileDysfunctionand
AntihypertensiveDrugs
The association of ED and vascular risk factors including
hypertension raises the hypothesis that endothelial dysfunc-
tion is the common link between erectile dysfunction and
cardiovascular disease. But a possible association between
ED and hypertension is much more intricate issue involving
other aspects, such as the hemodynamic interferences caused
by antihypertensive drugs.
There is a complex relationship among arterial hyper-
tension and erectile dysfunction that is explained by the
multifactorial pathophysiological process that take place in
both conditions (Figure 1). So, considering that it is still
matter of discussion if hypertension is cause or consequence
of endothelial dysfunction, it can inﬂuence ED severity or
it could appear before ED. Depending on the class of the
antihypertensive drug and its eﬀect over endothelium medi-
ators, the impact on ED could be positive or negative. PDE5
inhibitors, ED’s ﬁrst line therapy, present a mechanism of
action based on NO bioavailability. Lack of eﬃcacy could
represent a more intense vascular damage. In contrast, con-
tinuous use of PDE5 inhibitors proved to reverse endothelial4 International Journal of Hypertension
dysfunction with positive impact on sexual function and
even on blood pressure control.
In this sense, it is an usual popular belief to blame medi-
cal therapy for hypertension as the main reason of erectile
problems, especially when there is a temporal coincidence
of starting symptoms and use of antihypertensive drugs, in
particular when including the “old” diuretics and beta-
blockers [34]. In almost all trials where this topic was stud-
ied, ED was not the primary objective and was assessed by
patient reports instead of questionnaire evaluation or mea-
surementofpenilerigidity.So,thereisalackofdeﬁnitiveevi-
dence even with betablocker and diuretics. Recently, Baum-
h¨ akel et al. performed a systematic analysis of trials eval-
uating erectile function with a validated questionnaire or
direct assessment of penile rigidity and concluded that only
thiazide diuretics and betablockers, not including nebivolol,
may inﬂuence erectile function. ACE inhibitors, angiotensin
receptor blockers, and calcium channel antagonists were re-
ported to have no relevant or even a positive eﬀectonerectile
function [42].
Development of erectile dysfunction in connection with
betablockers might be biased by psychological eﬀects derived
from the awareness of being treated with a certain substance.
This is an important point since patient concerns about
the adverse eﬀects of drugs on erectile function might limit
the use of essential medications in cardiovascular high-risk
patients [43].
In the same way, data with diuretics and ED are not con-
clusive. A small number of patients and inadequate eval-
uation of erectile function limit the trials results. On the
other hand, the erectile dysfunction substudy in ONgoing
Telmisartan Alone and in combination with Ramipril Global
Endpoint Trial/Telmisartan Randomized AssessmeNt Study
in ACE iNtolerant subjects with cardiovascular Disease
(ONTARGET/TRANSCEND) did not demonstrate a signiﬁ-
cant association of pretreatment with diuretics with erectile
function in high-risk patients [44].
It is important to consider that drugs used for treat-
ment of cardiovascular diseases have often been accused of
inﬂuencing erectile function, and such belief could inﬂuence
drug compliance [42]. Some authors do not agree with a
class speciﬁc and constant eﬀect over erectile function [45].
Others believe that the hypotensive eﬀect of any drug could
produce ED in susceptible subjects with comorbidities [36].
More recently, Earden et al. showed that the presence of
“nondipper” pattern on ambulatory blood pressure monitor-
ingamongtreatedhypertensivepatientswerestronglyrelated
to worst erectile function independently of the number or
the class of antihypertensive drugs in use [46]. On the other
hand, small studies suggested that some antihypertensive
drug classes could have less harmful or even beneﬁcial eﬀect
on sexual function like calcium channel antagonists [47],
angiotensin II receptor blockers [44], and nebivolol [45].
There is no clinical trial evaluating the eﬀect of calcium
channel antagonists on erectile function with an adequate
assessment of ED, but they are reported to have no relevant
eﬀectonerectile function[47]. For drugs that act over renin-
angiotensin system, most evidence suggests that there was
no inﬂuence on erectile function, and some authors indicate
beneﬁcial eﬀect [42]. However, in 1549 cardiovascular high-
risk patients included in ONTARGET/TRANSCEND trial,
therewasneitherabeneﬁcialeﬀectoftheACEinhibitorram-
ipril, the angiotensin receptor blocker telmisartan, nor of the
combination of both on erectile function [48].
Favorable eﬀects on nitric oxide synthase and oxidative
stress have been shown with nebivolol pointing out a mech-
anism for improvement of erectile function. Experimental
studies have demonstrated an enhancement of endothelial
function in aorta and corpus cavernosum with a signiﬁcant
reductioninpenileoxidativestressandcollagencontent[49],
protected cavernosal tissue against structural changes, and
increased expression of endothelial NO synthase (eNOS)
[50].
Although no class of antihypertensive agents presents a
clearly superior eﬀect over the others in terms of quality of
life, the current impression is that nebivolol, ACE inhibitors,
and angiotensin II receptor antagonists may oﬀer some ad-
vantage,atleastinregardtoeﬀectsoncognitivefunctionand
sexual activity [51].
The presence of comorbidities and concomitant drugs,
a common situation in older hypertensive subjects, and
lack of diagnostic standardization concerning tools to access
erectile function impair a reliable analysis of trials about the
r e l a t i o n s h i pb e t w e e nE Da n dh y p e r t e n s i o na sw e l la sa n y
robust conclusion about deleterious action of antihyperten-
sive drugs on erectile function [52]. In this way, search for
new data on basic mechanism under ED development in
hypertensive individuals is an actual need. In an individual
aspect, sexual activity and erectile function quality should be
part of anamnesis before starting antihypertensive therapy
and seems to play a relevant role in the followup, as it would
allow a scalable monitoring of erectile function, help the
selection of better classes of antihypertensive drugs, turn
easier the identiﬁcation of adverse sexual events, and even
improve therapeutic compliance [51].
6.Pathophysiology ofEDin
HypertensivePatients
Several hypotheses try to explain the pathophysiology of ED
in hypertensive individuals. Since the pioneering work of
Jeremy et al. [53] who highlighted the role of endothelial
oxidative stress on the genesis of ED, other publications rein-
force this ﬁnding [54] even demonstrating that antioxidant
therapy could improve endothelial function with positive
interference on erectile function [55].
Old and more recent experimental studies have pointed
out the role of nitric oxide (NO) and other possible medi-
ators in endothelial dysfunction of hypertensive rats [56].
In spontaneously hypertensive rats, endothelial-mediated
relaxation of corporal cavernosal strips in response to ace-
tylcholine was signiﬁcantly impaired, suggesting a defect in
endothelium-dependent reactivity and a corresponding re-
d u c t i o ni nN O[ 57]. Perticone et al. demonstrated that en-
dothelial function of hypertensive patients had an inverse re-
lationship with L-arginin (NO precursor) levels and ADMA,
a competitive inhibitor of eNOS [58]. On the other hand,International Journal of Hypertension 5
decrease in NO production or bioavailability would take
place in the etiology of hypertension in several clinical sit-
uations [59] where ED is not always present. Thus, one pos-
sible mechanism by which hypertension may cause ED is
likely related to endothelial dysfunction associated with hy-
pertension. Long-standing hypertension may cause oxidative
stress,endothelialcellinjury,anditsconsequences,including
the inability of arteries, arterioles, and sinusoids of the cor-
pus cavernosum to dilate properly [60]. Some authors state
that ED symptoms in hypertensive patients would represent
deterioration in endothelial dysfunction already present and
should alert for a possible progression of a systemic vascu-
lopathy [61].
Corroborating this link among hypertension and ED,
Vlachopoulos et al. identiﬁed that hypertensive men had
greater carotid intima-media thickness, lower brachial ﬂow-
mediated dilation, and higher levels of serum inﬂamma-
tory mediators than normotensive individuals with similar
cardiovascular risk [62]. They suggested NO bioavailability
reduction caused by ADMA accumulation consequent of
high blood pressure as the molecular mechanism for these
ﬁndings. This and other authors [63] argue that ED should
represent a clinical sign of a deeper vascular damage in
hypertensive patients and an increased risk of cardiovascular
events. In this way, Prisant et al. showed that ED severity
among hypertensive subjects were associated with age, dura-
tion of hypertension, and presence of peripheral vascular
disease [64].
During COBRA (PolarCath Cryoplasty Versus Conven-
tional Balloon Postdilation of Nitinol Stents for Peripheral
Vascular Interventions) trial, Montorsi et al. evaluated 285
subjects with proved coronary arterial disease and identiﬁed
that ED symptoms began 2 to 3 years before clinical man-
ifestation of coronary disease [61]. Robust clinical trials
conﬁrm that ED is a strong cardiovascular event predictor
such as cardiovascular death, myocardial infarction, and
cardiac failure [48]. Chung et al. followed a cohort of ED
men and compared the 5-year encephalic vascular accident
risk with another cohort with similar cardiovascular risk but
normal erectile function. They conﬁrmed ED as a clinical
independent marker of increased cerebral vascular disease
risk [65].
As previously commented, the link between both condi-
tions seems to lie in the endothelium which performs many
functions that contribute to homeostasis and prevention of
atherosclerosis. Endothelial dysfunction is considered one of
the earlier steps of atherosclerosis process, preceding angio-
graphic, ultrasonographic, and clinical evidences of vas-
cular disease [66]. These clinical manifestations rarely are
symmetrical in the same patient, probably due to diﬀerent
sizes of arterial tree that irrigate territories such as penile,
heart, brain, and legs [20], and diﬀerent needs of blood
supply and vasodilation of each structure [67]. It has been
suggested that the small cavernosous arteries were more vul-
nerable to atherosclerosis when compared to larger arterial
trees like coronaries [20, 67] explaining why ED precedes
angina in a patient with systemic vasculopathy.
T h er o l eo fN Oa sam a j o rm e d i a t o ro fe r e c t i l ep a t h -
ways such as NO-GPMc and RhoA/Rho-kinase was well
documented [68]. Some experimental studies conﬁrmed
the participation of eNOS during erectile response [69]. In
penilecirculation,eNOSactivityandNObioavailabilitywere
regulated by several molecular mechanisms such phosphori-
lation, protein interactions, and oxygen reactive species that
control eNOS activity in physiological conditions and could
explain several situations where NO bioavailability could
decrease and manifest as ED [21].
Clinical evidences seem to conﬁrm this increased vulner-
ability of cavernosous circulation. Kaiser et al. observed that
NO-GMPc pathway was earlier damaged in atherosclerosis
process when they followed ED men without cardiovascular
disease and compared them with men with normal erectile
function. They found that vasodilation of the brachial
artery by both mechanisms, endothelium-dependent and
independent, was signiﬁcantly compromised in the group
suﬀering from ED, which illustrates that vascular alterations
involved in ED are a generalized process [67]. Accordingly
to these authors, possible reasons for the precocity of ED
as clinical manifestation of systemic atherosclerosis were the
small size of cavernosous arteries and the need of a huge
dilation, nearly 80%, in penile circulation for an adequate
blood supply for a full erection. This value contrasts with
the percentage of other territories where the dilation varies
from 10 to 20%. In addition, penile vascular tree seems to
be particularly dependent of NO as it participates on arterial
dilation to rapidly increase blood ﬂow but also mediates
cavernosous sinusoids and venous dilation that represents
a crucial step on venoclusive mechanism that assure the
obtaining and maintaining of a rigid erection. In several
other vascular territories, NO participation on venous side
of circulation is minimal or null [67].
Although aging and atherosclerosis are recognized risk
factors for ED development, according to some experimental
studiesthemechanismunderthosesituationsisdistinct[57].
While ED in atherosclerotic rabbit was a consequence of
endothelial and vascular smooth muscle cell dysfunctions in
consequence of ADMA accumulation [70], these were not
found in older animals with ED but without atherosclerosis
where possible pathophysiological mechanism would be the
hyperactivity of Rho/RhoKinase pathway [57].
Due to the lack of large clinical trials with long followup
period designed for ED identiﬁcation and with cardiovas-
cular morbidity and mortality as endpoints, it is premature
to assure that ED identiﬁes an increased cardiovascular risk
among hypertensive patients that extends beyond the risk
represented by blood pressure elevation [62]. Studies with
larger samples contradict small trials conclusions as they
have not observed any association of ED and antihyperten-
sive drugs, cholesterol levels, and even smoking [44]. New
randomized trials with appropriate design to clarify these
issues are still expected.
7. Therapeutic Approach of Hypertensive
Patients withED
Firstly, it is important to provide an adequate room to talk
about sexual dysfunction. It is crucial to listen carefully
what patient would like to explain and also to make some6 International Journal of Hypertension
questions to check what was understood. The usefulness of
standard questionnaires [71] during daily clinical practice is
low but the short form of IIEF (5 questions), for example,
couldhelptoconﬁrmtheEDdiagnosisandtoprovideaclear
tooltoquantifythepathologyandalsotofollowitsevolution
and clinical response to therapy [72].
Initial eﬀorts should identify and treat all modiﬁable risk
factors. Next step is a trial with PDE5 inhibitor for those
hypertensive subjects without contraindications for sexual
activity or for this class of drugs [11]. Thus, knowledge of
cardiovascular risk of men with ED is essential, since it
could help to identify hidden risk factors and also to eval-
uate the existence of any contraindication for ED therapy
as detailed in the second Princeton consensus [73]. In
this way, hypertensive patients would be classiﬁed as low,
intermediate, or high risk. In case of high risk, before sex-
ual attempts, a cardiologic evaluation is necessary in order
to improve conditions to support such metabolic demand
[74]. In high risk subjects, cardiologic condition should
be stabilized through medication, surgery, or other means
before sexual rehabilitation. In intermediate risk, a deeper
cardiovascular evaluation is necessary and eﬀorts to improve
clinical condition should precede sexual eﬀorts [73].
To assess the individual risk for cardiovascular diseases,
repeated measurement of blood pressure and biochemical
proﬁle, including fasting serum glucose, creatinine, and lip-
ids, is necessary. Body mass index, according to weight and
height,assessmentoflifestyle,actuallevelofphysicalactivity,
and potential genetic predisposition should also be obtained.
A resting electrocardiogram, should also be documented. If a
patienthasthreeormoreatherogenic-riskfactors,anexercise
electrocardiogram should be considered as per the Princeton
Consensus Panel. In some high risk patients, a Doppler-
sonographic examination of the carotid arteries and lower
extremity arteries might also be included into the workup
[73].
Cardiovascular disease is not a contraindication to sexual
activity in patients who have been properly assessed and
treated. In well controlled hypertensive subjects who take
one or two antihypertensive drugs and have no other risk
factors, indicating low cardiovascular risk, PDE5 inhibitors
could be tried. However, among those without treatment
or with inadequate blood pressure control or with severe
hypertension, it is recommended the cardiologic approach
and initial cardiovascular therapy before the prescription of
speciﬁc drugs to improve erectile function [74].
Patients with diabetes suﬀering from ED are at special
risk for silent cardiovascular disease [75]. Therefore, some
authorsrecommendanexercisetestforeverydiabeticpatient
presenting with ED, as a signiﬁcant number of patients with
silent ischemic heart disease will be detected [76]. If the
results suggest an increased risk for cardiovascular disease, a
referral to a cardiologist is reasonable for detailed diagnostic
testing and initiation of therapy [73]. Importantly, the heart
conditions should be carefully clariﬁed before initiation of
medical treatment, as PDE5 inhibitors must not be used
in certain cardiovascular conditions or at least require spe-
cial precaution. In addition, detailed recommendations for
cardiovascular patients, concerned about a potential risk of
sexual intercourse in the light of their underlying cardio-
vascular condition, are available both for further diagnostic
workup and therapeutic interventions according to the ﬁrst
and second Princeton Consensus Conference [74, 77].
Considering PDE5 inhibitors mechanism of action, it is
reasonable to expect for vascular hemodynamic interferen-
ces, eﬀects on blood pressure and coronary circulation alter-
ations, especially among hypertensive patients or those on
severalantihypertensivedrugs.However,bloodpressurelow-
ering eﬀects of the current PDE5 inhibitors are low, although
oral administration of sildenaﬁl was able to reduce systolic
and diastolic blood pressure by 7–10mmHg in a non-dose-
dependent manner [78]. When PDE5 inhibitors are admin-
istered to patients with hypertension who are taking most
antihypertensive agents (e.g., betablockers, angiotensin-con-
verting enzyme inhibitors, angiotensin receptor blockers,
calcium antagonists, diuretics), there are usually small addi-
tive decreases in blood pressure without a signiﬁcant in-
crease of adverse events. Similarly, eﬀects of sildenaﬁl on
blood pressure in hypertensive patients on multiple anti-
hypertensive drugs were minimal and well tolerated [79,
80]. Comparable results were obtained with newer PDE5
inhibitors vardenaﬁl and tadalaﬁl [80]. Some patients devel-
op orthostatic hypotension when PDE5 inhibitors are used
in conjunction with an alphablocker (typically for urologic
conditions, such as benign prostatic hypertrophy) but some
studies suggest that the interaction is less clinically relevant
if the patient has been undergoing long-term alpha-blocker
therapy [81]. On the other hand, some beneﬁcial eﬀects on
blood pressure control have been shown with PDE5 use in
hypertensive patients [82].
Although PDE5 inhibitors have been extensively used for
morethanonedecade,inadequateuseisstillonemajorcause
of therapeutic failure. Several studies showed that more than
ah a l fo fE Dm e nl e a v eo ﬃces with prescription of PDE5
inhibitor but without correct information about its posology
[83]. Most common mistakes include high fat meal near in-
take, lack of sexual stimulation after intake, short time before
sexual intercourse, and low number of attempts [84].
After cardiovascular risk stratiﬁcation and adequate con-
trolofmodiﬁableriskfactors,EDpatientsshouldbeoriented
about the right way of sexual medication usage. Although it
could sound obvious for doctors, it is prudent to emphasize
basic orientation (Table 1) as improper drug usage is a com-
mon reason for lack of eﬃcacy.
(i) Take PDE5 inhibitor at least one hour before sexual
intercourse (two hours when using tadalaﬁl).
(ii) Do not take PDE5 inhibitor near (less than two
hours) high fat meal or excessive alcohol consump-
tion.
(iii) Sexual stimulation is essential for PDE5 inhibitors
action.
(iv) Try more than once and ideally in diﬀerent situations
before giving up.
Even when patients return claiming nonresponse to
PDE5 inhibitor, it is recommended to check all steps whereInternational Journal of Hypertension 7
Table 1: How to adequately orientate during PDE5 inhibitors
prescription.
Make a cardiovascular evaluation that allows you know risk
stratiﬁcation.
If sexual intercourse is permitted but PDE5 inhibitors not—refer
to urologist.
Use adequate PDE5 inhibitors dosage.
Inform about the time interval to take drug before sexual
intercourse.
Avoid fat meal or alcohol intake near PDE5 inhibitor
consumption.
Alert about the necessity of sexual excitement to reach an erection
under PDE5 inhibitor.
Talk about psychological inﬂuence on PDE5 inhibitors
eﬃcacy-believe it.
T rya tl e a s tf o u rt os i xt i m e si nd i ﬀerent situations before giving up.
PDE5, phosphodiesterase-5.
medication were tried and review psychological conditions,
partner collaboration, blood pressure control, glucose and
cholesterol levels [83]. Low total testosterone has been
implicated in PDE5 failure. In countries where men have free
access to sexual drugs, the situation of improper use is even
more dramatic.
When clinical failure with PDE5 inhibitor is conﬁrmed,
urologist should participate and evaluate possible options to
allow an active and satisfactory sexual life. Intracavernosous
self-injection and penile prostheses constitute the most
common path for men refractory to oral therapy [11].
But besides referring to specialist, such lack of eﬃcacy
should be interpreted properly. We recently showed that
hypertensive men with ED who did not respond to 20mg
of vardenaﬁl had lower ﬂow mediated dilation and greater
intima media thickness, in addition to a higher Framingham
score, pointing to a direct clinical way to identify patients
who deserves special attention and probably more aggressive
cardiovascular therapy [85].
8. Why Asking about Sexual Life before Starting
AntihypertensiveDrugs?
Management of hypertension should take into account,
especially in elderly, the possible negative impact of anti-
hypertensive drugs on the patient’s quality of life, the
deterioration of which may reduce treatment compliance
[51]. Although ED has a high prevalence in the hypertensive
population, sexual questions are not frequently asked during
general practitioners consultations [37]. Many hypertensive
men do not recognize that they have ED and only a minority
of GP considers ED or other sexual issues for the treatment
of hypertension as either a possible adverse outcome or as a
factor to consider in treatment decision [86].
Knowledge about sexuality seems important as men and
women increased their life expectance and want to keep
quality of life during aging. Erectile function preservation
is essential for sexually active man while having a lower
Table 2: Reasons to ask about your patient’s sexual life during your
next consultation.
Increase empathy opportunity to improve doctor and patient
relationship.
High prevalence of ED among hypertensive men.
Patients concerns about the adverse eﬀects of drugs on erectile
function.
Meaning of ED as a cardiovascular risk marker.
Therapeutic options for ED easily available and with good eﬃcacy.
Knowledge of PDE5 inhibitor failure and its cardiovascular
implication.
Knowledge of possible sexual adverse eﬀects during
antihypertensive treatment.
Better therapeutic adhesion for drugs and life habits modiﬁcation.
Positive impact on patients and their partner quality of life.
ED, erectile dysfunction; PDE5, phosphodiesterase-5.
weightforotherwhohasnointercourses.Asexualevaluation
in GP visits could detect ED earlier and also help in risk
factors therapy customization, avoiding certain drug classes
that could disturb sexuality [87]. Besides high prevalence of
ED among hypertensive individuals, possible association to
EDseverityandimportantaspectsintherapeuticcompliance
improvementjustifytherelevanceofabriefsexualanamnesis
inoneoftheﬁrstvisitsinsideGPorcardiologistsoﬃces [88].
Evidences demonstrate that the successful treatment of ED is
associated with signiﬁcant improvements in overall physical
and emotional well-being [89].
Another interesting aspect of ED knowledge in hyper-
tensive subjects approach is that some evidences point out
to an improvement in blood pressure control maybe as a
consequence of better therapeutic compliance after PDE5
inhibitor therapy [82]. Likewise, Lamina et al. have shown
that hypertensive patients who start better life habits have
got an improvement in erectile function simultaneously
to serum inﬂammatory markers reduction, like C-reactive
protein [90].
Recent guidelines establish that patients without obvious
etiology for ED, such as anatomical disorders, neurological
disease, or endocrine causes, should be evaluated for car-
diovascular risk factors, arterial hypertension, and arterial
disease [91]. The relatively high probability of detecting
potentially serious diseases warrants further investigations
[75]. In addition, the strong association between cardio-
vascular risk factors and ED should be brought to the
patient’s attention, as this, in some patients, might be a more
convincing motivation to modify these risk factors, change
lifestyle, eﬀectively treat hypertension, quit smoking than
more abstract statistical association between cardiovascular
disease, and risk factors [92]. ED oﬀers a unique chance to
undergo medical examination and, therefore to, improve not
only their sexual but, most importantly, their overall health.
Table 2 highlights main reasons to take time and ask about
sexual life before starting antihypertensive therapy during
next consultation.8 International Journal of Hypertension
9. Conclusions
Despite high prevalence of ED among hypertensive men, it
is not often matter of discussion during consultation with
general practitioners. An adequate approach to identify
sexual health in primary care is needed to identify sexual
dysfunctions earlier and also to individualize treatment, to
prevent that this situation contributes to a reduction of ther-
apeutic adhesion and even worsens the quality of life among
people whoalready suﬀer from AH and other traditional risk
factors.
Sexual function knowledge by general practitioners and
cardiologists is relevant and should be ideally accessed before
starting therapy for hypertension. In addition to the high
prevalence of ED among hypertensive men, its association
with the severity of hypertension, and possible interference
aftertheintroductionofantihypertensivemedicationsjustify
the importance of including a brief sexual anamnesis during
clinical consultations.
After ED diagnosis and for those without contraindica-
tion for sexual activity or PDE5 inhibitors usage, doctors
must take time to adequately inform their patients about the
correct way to take sexual medication. Oral therapy failure
could represent a deeper vascular damage and worst cardio-
vascular risk and generally requires the aid of the urologist in
order to restore hypertensive man sexual life.
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